---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-034326"
form_type: "8-K"
ticker: "AMIX"
cik: "0001617867"
company_name: "Autonomix Medical, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:57:46.714660+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Autonomix Q2 FY2025 net loss $2.8M; PoC trial shows 100% of lead-in patients off opioids at 4-6 weeks

## Summary
- Net loss of $2.8M for three months ended Sept 30, 2024 vs $6.0M loss same quarter last year; cash $5.2M.
- 100% of lead-in responders zero opioid use at 4-6 weeks post-procedure; 83% pain reduction at follow-up.
- 60% enrollment reached in pancreatic cancer pain PoC trial; 79% responder rate with zero opioid use at 7 days.
- Upcoming milestones: complete enrollment Q4 CY2024, topline data 1H 2025, FDA clearance targeted 1H 2027.
- R&D expense $1.2M (vs $0.5M YoY) driven by clinical trial and product development costs.

## SEC filing metadata
- accession: 0001437749-24-034326
- form_type: 8-K
- ticker: AMIX
- cik: 0001617867
- company_name: Autonomix Medical, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1617867/000143774924034326/0001437749-24-034326-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1617867/000143774924034326/amix20241107_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-034326
- JSON: https://secwatch.observer/filing/0001437749-24-034326.json
- Plain text: https://secwatch.observer/filing/0001437749-24-034326.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.